# PushKang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pushkang

- Industry: Medical Devices & Equipment
- Headquarters: Shaoxing, China
- Website: www.pushkang.com.cn
- Total disclosed funding: $29M
- Latest round: Series C (Oct 24, 2022)
- Investors on record: 11

## About

Based in Shaoxing, China and founded in 2014, Zhejiang PushKang Biotechnology Co., Ltd is a biotechnology company specializes in the development of microfluidic coagulation in-vitro diagnostic instrument. The company passed the EU ISO 13485 quality system certification in July 2016 and obtained the product registration certificate for the fully automated coagulation analyzer (MC500) in 2018 and the registration certificate for the fully automated chemiluminescent immunoassay analyzer and D-dimer in 2019. It has more than 300 employees and owns more than 70 patents, 26 of which are granted invention patents, including 7 US patents as of 2022. In July 2025, PushKang raised an undisclosed amount of venture funding from new investor Prosperity Investment.

The company self-developed products include venous whole blood original tube on the machine testing system such as MC100 portable coagulation analyzer and MC510/550 automatic coagulation analyzer, centrifugal microfluidic fully automated POCT chemiluminescence immunoassay system, and centrifugal microfluidic biochemical POCT detection platform such as MS200 portable biochemical analyzer and MS100 portable biochemical analyzer.

The company generates revenue from providing clinical test services.

## Funding rounds

- Series C, Oct 24, 2022, $14M — Shiyue Capital, Yinglian Health Industry Fund, Shijie Investment, Changan Huitong Capital
- Series C, Feb 22, 2021, $15M — Furong Capital, Shanghai Jiantong Investment Partnership Enterprise, GL Ventures
- Series B, Apr 1, 2020 — Shanghai Jianyi Private Equity Fund Management, YuanBio Venture
- Series A, Dec 6, 2019 — Hangzhou Leiyu Investment Management
- Series A, Jan 3, 2017 — Yonghua Capital

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Hangzhou Leiyu Investment Management (https://capitalatlas.ai/funds/hangzhou-leiyu-investment-management) — Series A
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Series C
- Shanghai Jiantong Investment Partnership Enterprise — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- Shiyue Capital — Series C
- Yinglian Health Industry Fund — Series C
- Shijie Investment (https://capitalatlas.ai/funds/shijie-investment) — Series C
- Changan Huitong Capital (https://capitalatlas.ai/funds/changan-huitong-capital) — Series C